GC Biopharma Corp
GC Biopharma Corp
Explore linked clinical trials.9 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Phase 1 Study of GC1130A in Patients With Sanfilippo Syndrome Type A (MPS IIIA) | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Mucopolysaccharidosis III, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 3A | Active, not recruiting | Phase 1 | 2026-09-08 | NCT06567769 | |
| A Phase 1 Study to Evaluate the Safety and Immunogenicity of GC4006A in Healthy Adults | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 1 | 2026-07-27 | NCT07728396 | |
| A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years | DNA Virus Infections, Herpesviridae infectious disease, Infections, Varicella Zoster Virus Infection, chickenpox, viral infectious disease | Recruiting | Phase 3 | 2026-04-17 | NCT07054099 | |
| A proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease | Fabry Disesase | Recruiting | Phase 1 / Phase 2 | 2025-11-04 | NCT06858397 | |
| Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Primary Immunodeficiency Diseases, hereditary disease, immune system disorder, inborn error of immunity | Active, not recruiting | Phase 3 | 2025-07-25 | NCT04565015 | |
| Evaluation of the Effectiveness and Safety of Rozetel Tablet in Patients After PCI: A Multi-Center Observational Study | Dyslipidemias, Lipid Metabolism Disorders, Nutritional and Metabolic Diseases, cardiovascular disorder, hypertensive disorder, metabolic disease, vascular disorder | Active, not recruiting | Not stated | 2025-07-24 | NCT07084246 | |
| A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults | Tetanus-diphtheria-acellular Pertussis (Tdap) | Recruiting | Phase 1 / Phase 2 | 2025-07-10 | NCT06997627 | |
| A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. | Blood-Borne Infections, DNA Virus Infections, Digestive System Diseases, Hepadnaviridae infectious disease, Infections, hepatitis, hepatitis B virus infection, infectious disease, liver disorder, viral hepatitis, viral infectious disease | Recruiting | Phase 3 | 2025-06-25 | NCT05686759 | |
| A Study to Evaluate the Safety, Tolerability, PK and PD of Intracerebroventricular GC1123 in Patients with MPS Ⅱ | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Neurobehavioral Manifestations, Neurologic Manifestations, Nutritional and Metabolic Diseases, Skin and Connective Tissue Diseases, X-linked disease, connective tissue disorder, cutaneous mucinosis, hereditary disease, inborn carbohydrate metabolic disorder, inborn errors of metabolism, inherited neurodegenerative disorder, intellectual disability, lysosomal storage disease, metabolic disease, mucopolysaccharidosis, mucopolysaccharidosis type 2, nervous system disorder | Active, not recruiting | Phase 1 | 2024-10-15 | NCT05422482 |